Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 4, 2003, Pages 777-787

  Darmani, N A ^a   Janoyan, J J ^a   Kumar, N ^a   Crim, J L ^a  

^a A T STILL UNIVERSITY   (United States)

Author keywords

5 HIAA; 5 HT2A receptor; Cannabinoid CB1 receptor; DOPAC; Dopamine; Head twitch response; HVA; Release; Scratching; Serotonin; SR 141716A; SR 46349B; Vomit; Vomiting

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE; EPLIVANSERIN; HOMOVANILLIC ACID; RIMONABANT; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYPTOTIS PARVA; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HEAD TWITCH; HYPERACTIVITY; INSECTIVORE; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SCRATCHING; SEROTONIN BRAIN LEVEL; VOMITING;

CRYPTOTIS; CRYPTOTIS PARVA; EMESIS; RODENTIA;

EID: 0142011192     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00150-3     Document Type: Article

References (37)

1. Aceto M.D., Scates S.M., Lowe J. Cannabinoid precipitated withdrawal by the selective cannabinoid antagonist, SR 141716A. Eur. J. Pharmacol. 282:1995;R1-R2.
2. 2 function. Neuroscience. 91:1999;607-620.
3. Arévalo C., de Miguel R., Hernández-Tristán R. Cannabinoid effects on anxiety-related behaviors and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 70:2001;123-131.
4. Cadogan A.K., Alexander S.P.H., Boyd E.A., Kendall D.A. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. 69:1997;1131-1137.
5. Calignano A., LaRana G., Makriyannis A., Lyn S.Y., Betramo M., Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol. 340:1997;R7-R8.
6. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13:1999;243-281.
7. Colombo G., Agabio R., Lobina C., Reali R., Gessa G.L. Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol. 344:1998;67-69.
8. 9- tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 285:1998;1150-1156.
9. 3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis. J. Neural Transm. 105:1998;1143-1154.
10. 1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology. 24:2001;198-203.
11. 1 receptors in the least shrew. Pharmacol. Biochem. Behav. 69:2001;239-249.
12. Darmani N.A. The cannabinoid antagonist/inverse agonist SR 141716A reverses the antiemetic and motor depressant action of WIN 55,212-2 in the least shrew. Eur. J. Pharmacol. 430:2001;49-58.
13. 1 receptor antagonist/inverse agonist SR 141716A in naive mice. J. Neural Transm. 107:2000;931-945.
14. Gessa G.L., Casu M.A., Carta G., Mascia M.S. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur. J. Pharmacol. 355:1998;119-124.
15. Gifford A.N., Samiian L., Gatley S.J., Ashby C.R. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur. J. Pharmacol. 324:1997;187-192.
16. 9 dopamine neuronal activity in the rat. NeuroReport. 6:1995;207-209.
17. Heal D.J., Luscome J.P., Martin K.F. Pharmacological identification of 5-HT receptor subtypes using behavioral models. Marsden C.A., Heal D.J. Central serotonin receptors and psychotropic drugs. 1992;56-99 Blackwell, London.
18. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A.et al. International Union of Pharmacology, XXVII, Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-702.
19. 1 receptors. Naunyn-Schmeideberg's Arch. Pharmacol. 359:1999;65-70.
20. 9-THC and other cannabinoids. Pharmacol. Biochem. Behav. 71:2002;155-162.
21. 1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn-Schmeideberg's Arch. Pharmacol. 359:1999;466-470.
22. 3 receptor mutant mice. J. Neurosci. 18:1998;2231-2238.
23. Koller W.C. Levodopa in the treatment of Parkinson's disease. Neurology. 55:2000;S2-S7.
24. 1 receptors. Naunyn-Schmeideberg's Arch. Pharmacol. 361:2000;19-24.
25. Paris J.M., Cunningham K.A. Habenula lesions decrease the responsiveness of dorsal raphe serotonin neurons to cocaine. Pharmacol. Biochem. Behav. 49:1994;555-560.
26. 2 receptors. Pharmacol. Ther. 74:1997;129-180.
27. Pertwee R.G. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch. Komplement. 3:1999;12-15.
28. Rinaldi-Carmona M., Barth F., Healume M., Shire D., Calandra B., Congy C.et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
29. Rubino T., Patrini G., Massi P., Fuzio D., Vigano D., Giagoni G.et al. Cannabinoid precipitated withdrawal: a time course study of the behavioral aspects and its correlation with cannabinoid receptors and G protein expression. J. Pharmacol. Exp. Ther. 285:1998;813-819.
30. Rutter J.J., Gundlah C., Auerbach S.B. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse. 20:1995;225-233.
31. Ryan N.D., Birmaher B., Perel J.M., Dahl R.E., Meyer V., al-Shabbout M. et al. Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs. normal children. Arch. Gen. Psychiatry. 49:1991;843-851.
32. Schlicker E., Kathman M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22:2001;565-572.
33. Sim-Selley L.J., Brunk L.K., Selley D.E. Inhibitory effects of SR 141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414:2001;135-143.
34. 1 receptor antagonist SR 141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur. J. Pharmacol. 426:2001;R3-R4.
35. Veyrat-Follet C., Farinotti R., Palmer J.L. Physiology of chemotherapy-induced emesis and antiemetic therapy: predictive models for evaluation of new compounds. Drugs. 53:1997;206-234.
36. 2A receptor agonists into the prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282:1997;699-706.
37. 2C receptor agonists in the pigeon. Behav. Pharmacol. 11:2000;355-364.